NRx Pharmaceuticals (NRXP) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $50.00 from $49.00 | Oct 1, 2026 |
| BTIG | Maintained | Buy | $10.00 | Sep 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Aug 25, 2026 |
| BTIG | Maintained | Buy | $10.00 | Aug 18, 2026 |
| BTIG | Maintained | Buy | $10.00 from $25.00 | Aug 7, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | May 5, 2026 |
| Ascendiant Capital | Maintained | Buy | $49.00 from $48.00 | Apr 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Apr 27, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Apr 23, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Apr 20, 2026 |
| BTIG | Maintained | Buy | $25.00 | Mar 24, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Mar 24, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Mar 17, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Mar 16, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Mar 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 from $40.00 | Mar 3, 2026 |
| BTIG | Maintained | Buy | $25.00 | Feb 18, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Feb 17, 2026 |
| BTIG | Maintained | Buy | $25.00 | Jan 15, 2026 |
| D. Boral Capital | Maintained | Buy | $34.00 | Jan 5, 2026 |
Frequently asked questions
What is the price target for NRXP stock?
The average 12-month analyst price target for NRx Pharmaceuticals (NRXP) is $35.00, with a high estimate of $50.00 and a low of $10.00, across 3 analysts.
Is NRXP a buy, sell, or hold?
Analysts covering NRx Pharmaceuticals currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NRXP?
The average price target of $35.00 implies 1238.43% upside from the last price of $2.62.
What is the latest analyst rating on NRXP?
On Oct 1, 2026, Ascendiant Capital maintained NRx Pharmaceuticals at Buy with a price target of $50.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.